We strive to enhance the lives of cancer patients across the globe with our range of high quality medicines at affordable pricing.
Finished Dosage Formulations (FDF)
Globela is a leading manufacturer of FDF (finished dosage formulations) pharmaceutical products. Our FDFs are some of the best in the market due to their high quality, safety and efficacy levels and consistent performance.
A finished dosage formulations (FDF) is a pharmaceutical product that is a finalized drug ready for consumption. Drug formulations available are tablets, capsules, dry syrups and pellets.
We design and manufacture effervescent tablets that have a pleasant taste, even if they contain bitter, sulfuric, sour, metallic, astringent, or difficult-to-process APIs.
Effervescent tablets dissolve quickly in water and have rapid action. The active compound of the drug becomes available in the solution, hence increasing its absorption in the system. It increases a patient’s liquid intake and bypasses the difficulty of swallowing large pills.
All our effervescent products dissolve quickly and completely leaving no residues or foam and are very stable, being less sensitive to humidity and high temperatures and can be used in tropical regions (climatic zones III- IV).
Globela’s commitment to quality and sustainability has made us a trusted name in the industry for various Therapeutic areas.
Therapeutic Areas
DC Granules and Pellets
DC Granules and Pellets intermediate between API and Finished formulations, can be used to make both single-compound tablets and tablets with multiple ready-to-fill DC Granules or Pellets.
Procuring DC granules and Pellets from Globela, saves a lot of time for our customers by making it easy to register and put products on the market quickly without having to invest in expensive product development.
Outsourcing DC granules also helps our customers simplify their supply chain management, reduce regulatory hassles, lowers testing costs and more.
Our production facilities are WHO GMP as well EU GMP certified and are working with well established API manufacturers.
The granulation process increases the size of the particles by turning fine or coarse powders into physically strong, larger granules that are all the same shape, flow well, and can be compressed well.
We make available different DC granules each with their own particle size distribution (PSD) and concentration and outsourced as per customer requirements.
We manufacture Taste-masked granules, designed to mask the original taste of the pharma product, which may not be easy to ingest. Taste-masked granules increase a medicine acceptance rate in the patients.
We also manufacture Pellets, the multiparticulate formulations created by the agglomeration of fine powdered excipients and drugs into small, free flowing, uniformly sized spheroids or semi spherical particles in various sizes as per the requirements.
We strive to bring to you the granules and pellets of effective quality, efficient timelines and optimum rates, always.
API & Intermediates
API (Active Pharmaceutical Ingredient) refers to the active ingredient in a drug that is responsible for its therapeutic effect. API is typically produced by pharmaceutical companies and then sold to other companies that formulate and manufacture the final drug product.
The API is the main component of the drug and is often the most expensive and difficult to produce and develop.
Intermediates, on the other hand, are compounds that are produced during the synthesis of the API. They are typically produced in large quantities and are not the final product, but rather an intermediate step in the production process. Intermediates are often used in the production of multiple API and are typically less expensive than the API itself.
Both API and intermediates being the critical components in the pharmaceutical industry, the production and handling of API and Intermediates are strictly regulated to ensure the safety and quality of the final drug products.
Services
Contract Research and
Manufacturing Services (CRAMS)
Contract research and manufacturing services (CRAMS) facilities by Globela provide a range of services to pharmaceutical companies, including research and development (R&D), clinical trials, and development and manufacturing of drugs and other medical products. These services allow pharmaceutical companies to outsource certain aspects of their operations, benefitting from our expertise and at the same time saving time and resources to focus on other areas of their business. Here are the three advantages of accessing our CRAMS services.
Globela’s CRAMS facilities help our partners by providing access to specialized expertise and state of art technology and equipment, if it is not present in house. This allows them to access the knowledge and resources they need to advance their research and development efforts without having to invest in their own infrastructure.
Moreover, Globela’s CRAMS facilities help pharmaceutical companies by providing cost-effective solutions and increasing their efficiency.
Additionally, Globela’s CRAMS facilities can help pharmaceutical companies navigate the complex regulatory landscape. The process of bringing a new drug or medical product to market can be complex and time-consuming, and requires compliance with a wide range of regulations.
Globela’s services help our partners to advance their research and development efforts, bring new treatments in the healthcare field, and improve the lives of patients around the world.
Contract Development and Manufacturing Organization (CDMO)
A Contract Development and Manufacturing Organization (CDMO) is a type of company that provides contract research and manufacturing services to the pharmaceutical industry. CDMOs are typically specialized in the development and production of active pharmaceutical ingredients (API), intermediates, and final drug products.
They offer a range of services, including research and development, clinical trials, manufacturing, and quality control. Globela offers CDMOs to other pharmaceutical companies to outsource certain activities in order to reduce costs, improve efficiency, and access specialized expertise and technology. CDMOs are an important part of the pharmaceutical supply chain, as they help to ensure the safe and effective production of drugs.
Tech Transfer for FDF, APIs
and Advance Intermediaries
Tech transfer, or technology transfer, is the process of transferring a technology or a process from one organization to another. In the pharmaceutical industry, this typically refers to the process of transferring knowledge, experience, and expertise in drug development from one organization, such as a research institute or university, to another, such as a pharmaceutical company.
Globela has acquired expertise in Tech Transfer that involves smooth transferring of knowledge about a specific drug or therapeutic agent, as well as expertise in drug development processes, regulatory affairs, and manufacturing. Our efficient Tech Transfer services can help our partners to accelerate the development and commercialization of new drugs.
